It is a novel genetic screening method based on the analysis of cell-free fetal deoxyribose nucleic acid (cff-DNA) In the maternal plasma. The genetic screening is performed between 10-22 weeks of time frame, with small amount of blood sample and requires a minimum of 10 weeks of pregnancy for APT results.
NiPT is commercializing at a rapid pace due to emerging technologies for non-invasive analysis of the fetal genome, thus reducing the cost-effectiveness of NiPT. The exponential growth of the NiPT market Is supported by various factors, such as reimbursement policies, insurance coverage, high incidence rate of Down syndrome, no risk of miscarriage with NiPT, and shifting trend toward child birth at an advanced maternal age (35 ears or above). Currently, NiPT Is considered as a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders.
Moreover, a complexity of diagnosis with 2nd generation sequencing (2GS). The 2GS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders.